Chondromyxoid Fibroma

Chondromyxoid fibroma (CMF) is the rarest benign cartilaginous tumour: under 1% of all primary bone tumours and about 2% of benign bone tumours. Jaffe and Lichtenstein described it in 1948, and it remains one of the most diagnostically challenging bone lesions, partly because it is so rare and partly because it can mimic chondrosarcoma both radiographically and histologically. Most orthopaedic surgeons will meet only a handful of cases in a career, and the lesion is often misdiagnosed at first, so a high index of suspicion and expert pathology review are the foundation of getting it right.

Who. The peak age is 10-30 years, the second to third decade, with a male predominance of 2:1.

Where. The metaphysis of a long bone is the usual site (70%), particularly around the knee. The proximal tibia is the single most common location:

• Proximal tibia - 25-30%
• Distal femur - 15%
• Pelvis - 15%, especially the iliac wing; pelvic involvement is more common than with other benign cartilaginous tumours
• Rare sites - skull, ribs, small bones of the hands and feet

Rare axial lesions (ribs, skull base) bring their own problems: anatomical constraints, and difficulty distinguishing them from chordoma or chondrosarcoma.

Natural history. CMF grows slowly and is locally aggressive. It is often asymptomatic and found incidentally; where there are symptoms they have usually been present for months to years. Local recurrence after curettage is the practical problem, and malignant transformation is exceedingly rare.

Origin. The cell of origin is still debated. The theories:

• Cartilage rest - aberrant cartilage differentiation from primitive mesenchyme
• Metaplastic - fibrous tissue undergoing cartilaginous metaplasia
• Neoplastic chondroblast - a benign proliferation of immature cartilage-forming cells

Behaviour. CMF is benign but locally aggressive, growing slowly by expansion and endosteal erosion. Unlike the true cartilaginous neoplasms (enchondroma, chondrosarcoma) it lacks classic hyaline cartilage and instead contains abundant myxochondroid matrix, both myxoid and chondroid. That composition places it between fibrous and cartilaginous lesions, which is what the name "chondro-myxo-fibroma" records.

Molecular hallmark. CMF is now defined molecularly by recurrent rearrangement of the GRM1 gene (encoding metabotropic glutamate receptor 1), in which GRM1 is placed under a constitutively active promoter and over-expressed (Torrence D et al., Histopathology 2024 — DOI). Break-apart FISH detects the rearrangement in roughly 75% of cases, while GRM1 immunohistochemistry is the most sensitive surrogate and is positive in around 97% of CMF yet negative in chondrosarcoma, enchondroma, chondroblastoma, giant cell tumour and other mimics (Toland AMS et al., Am J Surg Pathol 2022 — DOI). This makes GRM1 testing the single most useful ancillary tool when CMF must be separated from low-grade chondrosarcoma on a difficult biopsy.

Gross appearance. The tumour is grey-white to tan-yellow, firm and lobulated, rubbery to gritty, and well circumscribed, sometimes with a thin shell; there may be occasional haemorrhage and focal cystic degeneration. At surgery the cortex is thinned and expanded from within with the characteristic endosteal scalloping, there is usually no soft-tissue extension, and a pseudocapsule is often present. Curettage yields gelatinous to gritty tissue: the gelatinous consistency is the myxochondroid matrix, so the surgeon feels what the pathologist will see.

The lobule. Lobular architecture is the most distinctive histological feature. Lobules are separated by fibrous septa, and each shows the same zonal variation in cellularity:

1. Central zone - sparse stellate and spindle cells in abundant myxoid or chondroid matrix
2. Intermediate zone - increased cellularity with chondroblast-like cells
3. Peripheral zone - a hypercellular rim of spindle cells, stellate cells, osteoclast-like multinucleated giant cells and reactive bone

The pattern repeats throughout the lesion. Zonation is an architectural feature and is best appreciated on low power; a pathologist who starts on high power sees only the alarming cellular rim.

Why it is misread. The rim can look pleomorphic, but there is no true anaplasia: nuclei are bland and there is no permeative growth. That zone, sampled in isolation on a small biopsy, is the reason CMF is mistaken for chondrosarcoma.

Calcification. Uncommon, unlike other cartilage tumours. When present it is focal and stippled within the myxoid matrix, not the ring-and-arc pattern of enchondroma, so a heavily calcified cartilage lesion should make you reconsider the diagnosis.

Immunohistochemistry. Staining is variable:

• S100 protein - positive in chondroid areas, confirming cartilaginous differentiation
• Vimentin - diffusely positive
• Keratin - usually negative
• Sox9 - positive in chondrogenic cells
• Ki-67 - low proliferation index (under 5%), confirming the benign nature
• GRM1 - overexpressed; a sensitive, relatively specific marker for CMF

WHO. Chondromyxoid fibroma is classified as a benign cartilaginous tumour with low risk of local recurrence and no metastatic potential.

Enneking. Benign tumours are staged by behaviour, and the stage points at the treatment. S2 (active) lesions require treatment with extended curettage and an adjuvant; S1 (latent) lesions may be observed if incidental and asymptomatic; S3 (aggressive) features should raise suspicion of chondrosarcoma and call for expert review.

View larger

By site within the bone. Metaphyseal lesions are the most common (90%) and have the typical appearance. Diaphyseal lesions are less common and may be larger at presentation; epiphyseal lesions are rare and more difficult to reach surgically.

By behaviour. A primary lesion at first presentation is the usual case. A recurrent lesion after prior treatment carries a higher suspicion of grade if it behaves aggressively.

Symptoms. Pain is the most common symptom: dull, aching and intermittent, of gradual onset over months to years. A palpable swelling appears in superficial locations, and motion may be limited when the lesion is near a joint. Night pain is uncommon, unlike osteoid osteoma. 20-30% are discovered incidentally on imaging done for another reason.

Examination. There may be mild swelling over the metaphysis, and the lesion is firm, fixed to bone and non-tender or mildly tender. The joint usually has a normal range of motion, the limb is typically neurovascularly intact, the skin shows no warmth, erythema or other change, and there is no regional lymphadenopathy.

Pathological fracture. Unlike the more aggressive lesions (ABC, GCT), pathological fracture through a CMF is rare, because growth is slow and the cortical shell is preserved. When a fracture does occur it suggests one of three things:

• A large lesion with significant cortical thinning
• Trauma to weakened bone
• More aggressive behaviour warranting wide excision

A fracture does not change the benign nature of the lesion, but it may necessitate staged treatment: healing first, then definitive surgery.

Unusual presentations. Rarely CMF presents through its location:

• Spine - neurological symptoms from cord or nerve root compression
• Sacrum - bowel or bladder symptoms mimicking chordoma
• Rib - chest wall mass, respiratory symptoms
• Skull base - cranial nerve palsies, headaches

Diagnosis first. Tissue comes before treatment: an image-guided core needle biopsy with expert musculoskeletal pathology review and radiological correlation, confirming the lobular myxoid pattern before any definitive surgery.

Then staging and selection. Complete the imaging with plain radiographs and MRI (or CT if MRI is contraindicated) to assess cortical integrity, intramedullary extent, soft-tissue extension and proximity to neurovascular structures; on the Enneking system CMF is benign, stage 3 if it shows aggressive features. Treatment is then chosen on lesion size, location, symptoms, cortical involvement, patient age and functional demands, from observation, extended curettage with adjuvants, wide excision or en bloc resection, and every patient enters surveillance afterwards.

Algorithm

View larger

Observation. Most cases warrant surgery, because of the risk of continued growth and pathological fracture and because of diagnostic uncertainty; given how rarely CMF is seen and how easily it is misdiagnosed, most surgeons advocate curettage both as treatment and to obtain adequate tissue for a definitive histological diagnosis. Observation is suitable only for truly asymptomatic, stable, small lesions in low-risk locations where biopsy has definitively confirmed the diagnosis. The indications:

• Small, asymptomatic, incidental finding
• Lesion in a stable phase (no growth on serial imaging)
• Patient unwilling to undergo surgery
• High surgical risk (medical comorbidities)
• Elderly patient with limited life expectancy

An observed lesion is examined every 3-6 months for 2 years, radiographed every 6 months for 2 years and then annually, and imaged with MRI if symptoms change or the radiograph shows growth. Surgery follows if the lesion enlarges, symptoms worsen or cortical breakthrough develops.

Extended curettage with adjuvants. This is the gold-standard treatment for most CMF. The goals are to remove all tumour tissue, destroy residual microscopic disease with an adjuvant, fill the defect to restore structural integrity, and keep morbidity below that of wide excision. The operation, a cortical window, aggressive curettage of all lobular tissue, high-speed burring of the cavity walls and a local adjuvant (phenol, liquid nitrogen, argon beam or PMMA), is set out step by step in the Surgical Technique section.

Wide excision or en bloc resection. Reserved for specific scenarios:

1. Recurrent disease - after failed curettage, especially multiple recurrences
2. Aggressive features - soft-tissue extension, cortical destruction, pathological fracture
3. Expendable bone - fibula, rib, distal ulna, where excision has minimal morbidity
4. Diagnostic uncertainty - concern for low-grade chondrosarcoma on imaging or biopsy
5. Failed adjuvant therapy - multiple recurrences despite adjuvants

Wide excision carries significantly higher morbidity (loss of bone, need for reconstruction, functional deficit) but the lowest recurrence risk, under 5%.

Recurrence. A recurrence is picked up on surveillance imaging (the signs are described under Postoperative Care); biopsy if the imaging is unclear. A first recurrence is treated by repeat extended curettage with a more aggressive adjuvant, cryotherapy if phenol was used initially, with fresh tissue sent to confirm the diagnosis and rule out malignant transformation. After a second recurrence consider en bloc resection, especially if the bone is expendable or there is diagnostic uncertainty, since multiple recurrences may indicate sampling error with an underlying low-grade chondrosarcoma. If biopsy of a recurrence shows chondrosarcoma, proceed to wide resection with margins.

Planning. Review all imaging (X-ray, CT, MRI) to plan the cortical window, identify the neurovascular structures at risk, decide on reconstruction (bone graft, PMMA or allograft) and consent the patient for a possible pathological fracture during curettage. Position according to the lesion, with a tourniquet for extremity lesions.

1. Exposure and window. The incision lies directly over the lesion, avoiding a weight-bearing surface, with subperiosteal dissection that preserves the periosteum for closure. The window is cut with osteotomes or a saw directly over the lesion through the thinnest cortex, sized to expose the entire lesion so that every margin can be seen, and kept for use as autograft. In the skeletally immature, avoid the physis.

2. Intralesional curettage. Remove all visible tumour piecemeal with curettes of varying sizes, large first then small, confirming the lobular, gelatinous appearance consistent with CMF. Send multiple samples for histology, with a frozen section to confirm the diagnosis if this is the first surgery. Curettage must reach healthy bone circumferentially, extending 1-2mm beyond the visible tumour margin.

3. Extended curettage with the high-speed burr. A high-speed pneumatic burr removes a further 1-2mm of the cavity wall over the whole 360 degrees (floor, walls and ceiling), leaving smooth walls and removing microscopic residual tumour, followed by copious irrigation to clear bone debris. The burr is the standard adjuvant with a low complication rate, and extended curettage with it reduces recurrence from 25% to approximately 10%; adding phenol or cryotherapy decreases recurrence further but increases complication risk (pathological fracture, wound-healing problems). A combination may be used for high-risk lesions.

4. Local adjuvant. Apply the adjuvant to the cavity walls; the options, how to choose between them and the technique for each are set out below.

5. Filling and reconstruction. Fill the cavity completely, to prevent haematoma and provide structural support, with a filler chosen by cavity size, location and load:

• Small cavities (under 3cm) - cancellous autograft or allograft chips
• Large cavities - PMMA cement (immediate weight-bearing) or structural allograft
• Metaphyseal cavities near a joint - consider cancellous graft to preserve future arthroplasty options

Large cavities near joints may require structural support, a cortical strut or plate fixation, and prophylactic plate fixation should be considered where the cortex is extensively thinned.

6. Closure. Replace the cortical window as autograft if preserved, close the periosteum over it where possible to enhance healing, and close the subcutaneous tissue and skin in layers. A drain is optional; some surgeons use one for large cavities.

Phenol. A spill causes a chemical burn with soft-tissue necrosis, contact with a major nerve causes neurotoxic damage, and systemic toxicity (metabolic acidosis) is rare with local use. Prevention is protecting the soft tissues with moist pads, keeping phenol off nerves and limiting the volume.

Cryotherapy. Bone necrosis raises the pathological fracture rate to up to 10-15%, adjacent nerves suffer cold injury (the peroneal nerve at the proximal tibia), and the skin necroses if the cryoprobe is too close to it. Prevention is prophylactic fixation in weight-bearing bones, identifying the nerves and monitoring the freeze.

PMMA. The exothermic heat (60-80°C) can damage soft tissues and nerves, cement can extravasate into the joint or soft tissues, and the cement is difficult to remove if a joint replacement is needed later. Vent the heat, protect the soft tissues, and avoid PMMA in young patients near joints.

Bone graft. Graft resorbs, especially allograft; fracture through the graft follows inadequate incorporation or premature loading; and infection is higher with allograft (0.5-1%). Prevention is adequate fill, protected weight-bearing and antibiotics for allograft.

Long-term. Some patients are left with chronic pain or reduced function, especially in weight-bearing locations:

• Stiffness - prolonged immobilisation or adhesions
• Weakness - muscle atrophy during non-weight-bearing
• Pain - altered biomechanics, hardware irritation
• Limb length discrepancy - premature physeal closure in the skeletally immature

These are managed with aggressive physiotherapy, pain management, hardware removal if symptomatic and osteotomy for limb length inequality.

Malignant transformation. Exceedingly rare, with fewer than 10 reported cases. When it occurs it is unclear whether it represents:

1. True malignant transformation of a benign CMF
2. Initial misdiagnosis with an underlying low-grade chondrosarcoma
3. Radiation-induced sarcoma, if prior radiation was given

Most experts believe cases of "malignant CMF" are sampling errors at the initial diagnosis, which is another argument for adequate tissue sampling and expert pathology review.

The wound. A sterile dressing stays on for 48-72 hours, a drain, if placed, comes out when output is under 30mL in 24 hours, and sutures or staples are removed at 10-14 days. Watch for erythema, drainage or fever.

Analgesia. Multimodal, with paracetamol and opioids as required; ice and elevation control swelling, and a regional nerve block suits upper-limb surgery. Avoid NSAIDs for the first 6 weeks, as they impair bone healing.

Surveillance. Most recurrences occur within 24 months. Lifelong surveillance is recommended, with the most intensive monitoring in the first 5 years.

Signs of recurrence. On the plain radiograph:

• New lysis - lucency within the previously grafted area
• Loss of trabeculation - disappearance of the bone graft trabecular pattern
• Cortical erosion - scalloping or thinning of the cortex
• Soft-tissue mass - visible soft-tissue swelling

On MRI, if obtained:

• High T2 signal - the very bright myxoid recurrent tumour
• Lobulated mass - the characteristic lobular pattern
• Cortical breach - extension beyond the original cavity
• Soft-tissue extension - an extra-osseous component

Recurrence or healing? Early post-operative radiographs may show apparent lysis as graft resorbs during creeping substitution, which is normal healing. Four things separate the two:

1. Timing - normal resorption occurs at 6-12 weeks; recurrence typically after 6 months
2. Pattern - normal resorption is diffuse throughout the graft; recurrence is a focal lucency
3. Stability - normal resorption stabilises and then remodels; recurrence progressively enlarges
4. Symptoms - normal healing is painless; recurrence may cause pain

When in doubt, MRI or biopsy settles it.

Overall. CMF is a benign tumour with an excellent prognosis. There are no cases of metastasis, and the primary concern is local recurrence, which can be managed with repeat curettage or wide excision without any impact on survival.

Function. Outcomes are excellent for upper-limb lesions (near-normal function after healing), for the fibula (no deficit if the peroneal nerve is preserved), for small lesions (full return to the pre-morbid activity level) and in young patients, whose bone remodels and adapts well. The limitations come with large metaphyseal lesions (residual stiffness or weakness), pathological fracture (prolonged recovery, possible chronic pain), multiple recurrences (cumulative surgical morbidity) and wide excision (loss of bone and reconstruction-related problems).

The long-term data. Long-term studies are limited by the rarity of CMF, but the available evidence shows:

• 10-year tumour-free survival - 90-95% with curettage and adjuvant
• Functional scores - MSTS (Musculoskeletal Tumor Society) scores average 25-28/30, excellent
• Return to sport - most patients return to their pre-injury activity level by 6-12 months
• Quality of life - comparable to the general population after successful treatment

Global Epidemiology

Chondromyxoid fibroma is genuinely rare worldwide. In the Mayo Clinic series of 278 cases (Wu CT et al., Hum Pathol 1998 — DOI) CMF accounted for well under 1% of all primary bone tumours, with a slight male predominance and a peak in the second decade. Almost half of lesions arose in the long bones (classically around the knee), with the ilium and the small bones of the hands and feet as other characteristic sites. These distribution and demographic patterns are consistent across North American, European (Rizzoli — Gherlinzoni F et al., J Bone Joint Surg Am 1983 — DOI) and other international series, so the same diagnostic and surgical principles apply globally rather than being region-specific.

Guidelines and Standards — Side-by-Side

CMF is too rare to have a dedicated single-disease guideline; it is managed within broader bone-tumour/sarcoma frameworks. The table summarises how the major bodies converge on the same core message — refer, biopsy correctly, avoid radiotherapy.

Registry and Practice Variation

Perioperative Medication Principles (Generic, Globally Applicable)

Return to Function (Surgery-Driven, Not Jurisdiction-Driven)

Return-to-activity timelines depend on reconstruction type and weight-bearing status rather than any specific health or compensation system:

• Sedentary work / desk-based activity: approximately 2-4 weeks (upper limb), 6-8 weeks (lower limb)
• Light manual work: approximately 6-12 weeks, guided by radiographic graft incorporation
• Heavy manual / impact loading: approximately 3-6 months, after radiographic union and adequate graft incorporation

High-Yield MCQ Topics

Classic Exam Vignettes

Common Examiner Questions

1. Why is CMF easily misdiagnosed as chondrosarcoma?

   • Hypercellular peripheral zones can mimic malignancy on small biopsies
   • Both show high T2 signal on MRI
   • Expert pathology review essential

2. What is the significance of the lobular architecture?

   • Pathognomonic feature of CMF
   • Lobules separated by fibrous septa
   • Central myxoid zone, peripheral hypercellular zone

3. How do you reduce recurrence risk?

   • Extended curettage (not simple curettage)
   • High-speed burr to remove 1-2mm of cavity walls
   • Local adjuvant (phenol, cryotherapy, or PMMA)
   • Complete filling of defect with bone graft

4. When would you recommend wide excision over curettage?

   • Recurrent disease (especially second recurrence)
   • Expendable bone (fibula, rib)
   • Diagnostic uncertainty with concern for chondrosarcoma
   • Patient preference for lower recurrence risk

5. What is the prognosis?

   • Excellent (benign tumor)
   • 100% 5-year survival
   • No metastatic potential
   • Recurrence does not affect survival

1. Jaffe HL, Lichtenstein L. Chondromyxoid fibroma of bone: a distinctive benign tumor likely to be mistaken especially for chondrosarcoma. Arch Pathol. 1948;45:541-551.

2. Wu CT, Inwards CY, O'Laughlin S, et al. Chondromyxoid fibroma of bone: a clinicopathologic review of 278 cases. Hum Pathol. 1998;29(5):438-446. PMID:9596266. doi:10.1016/s0046-8177(98)90058-2

3. Rahimi A, Beabout JW, Ivins JC, Dahlin DC. Chondromyxoid fibroma: a clinicopathologic study of 76 cases. Cancer. 1972;30(3):726-736.

4. Gherlinzoni F, Rock M, Picci P. Chondromyxoid fibroma. The experience at the Istituto Ortopedico Rizzoli. J Bone Joint Surg Am. 1983;65(2):198-204. PMID:6337162. doi:10.2106/00004623-198365020-00008

5. Wilson AJ, Kyriakos M, Ackerman LV. Chondromyxoid fibroma: radiographic appearance in 38 cases and in a review of the literature. Radiology. 1991;179(2):513-518. PMID:2014302. doi:10.1148/radiology.179.2.2014302

6. Schajowicz F, Gallardo H. Chondromyxoid fibroma (fibromyxoid chondroma) of bone. A clinico-pathological study of thirty-two cases. J Bone Joint Surg Br. 1971;53(2):198-216.

7. Zillmer DA, Dorfman HD. Chondromyxoid fibroma of bone: thirty-six cases with clinicopathologic correlation. Hum Pathol. 1989;20(10):952-964. PMID:2793160. doi:10.1016/0046-8177(89)90267-0

8. WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2020.

9. Xu H, Nugent D, Monforte HL, et al. Chondromyxoid fibroma of bone: a retrospective study of 107 cases. Clin Orthop Relat Res. 2015;473(3):1097-1104. doi:10.1007/s11999-014-4066-7

10. Marcove RC, Kambolis C, Bullough PG, Jaffe HL. Fibromyxoma of bone. A report of 23 cases. Clin Orthop Relat Res. 1976;(118):156-162.

11. Bloem JL, Mulder JD. Chondromyxoid fibroma: a clinical and radiological study of 76 cases. Skeletal Radiol. 1985;14(1):7-13. doi:10.1007/bf00361194

12. Springfield DS, Rosenberg AE, Mankin HJ, Mindell ER. Relationship between osteofibrous dysplasia and adamantinoma. Clin Orthop Relat Res. 1994;(309):234-244.

13. Huvos AG. Bone Tumors: Diagnosis, Treatment, and Prognosis. 2nd ed. Philadelphia: WB Saunders; 1991:283-294.

14. Unni KK, Inwards CY. Dahlin's Bone Tumors: General Aspects and Data on 10,165 Cases. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2010:91-98.

15. Murphey MD, Walker EA, Wilson AJ, Kransdorf MJ, Temple HT, Gannon FH. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. Radiographics. 2003;23(5):1245-1278. doi:10.1148/rg.235035134

16. Kilpatrick SE, Wenger DE, Gilchrist GS, et al. Langerhans' cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer. 1995;76(12):2471-2484.

17. Bertoni F, Unni KK, Beabout JW, Sim FH. Chondrosarcomas of the synovium. Cancer. 1991;67(1):155-162.

18. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press; 2013.

19. Douis H, Saifuddin A. The imaging of cartilaginous bone tumours. I. Benign lesions. Skeletal Radiol. 2012;41(10):1195-1212. doi:10.1007/s00256-012-1427-0

20. Giudici MA, Moser RP Jr, Kransdorf MJ. Cartilaginous bone tumors. Radiol Clin North Am. 1993;31(2):237-259.